Our Company
About Us
Executive Team
Board of Directors
Scientific and Clinical Advisors
Partners
Our Science
Overview
CD6-ALCAM Pathway
Itolizumab
Publications & Presentations
Pipeline
Overview
Pipeline Graphic
Clinical Trials
Patients
Overview
Therapeutic Areas
Graft-Versus-Host Disease
Uncontrolled Moderate to Severe Asthma
SLE / Lupus Nephritis
Clinical Trials
The EQUATE study
The EQUIP study
The EQUALISE Study
Investors
Investors Overview
Stock Quote & Chart
Historical Price Lookup
News
Events & Presentations
Analyst Coverage
SEC Fillings
Governance Highlights
Committee Composition
Investor FAQ
Alerts & Contacts
Careers
Contact Us
Menu
EQUATE, a Phase 1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of a novel targeted anti-CD6 therapy, itolizumab, in subjects with newly diagnosed acute graft versus host disease
John Koreth et. al., 2019
Scroll to top